Discussion. Oncogenic osteomalacia is a rare paraneoplastic syndrome of skeletal dem ineralization from renal phosphate loss. Patients with this disorder have the characteristic clinical, laboratory, and radiographic ® ndings of hyperphosphaturic osteomalacia. Although the pathophysiology has not yet been clearly delineated, a humoral factor produced by the tumor is suspected to be the cause. Pur pose. We report the ® rst case of oncogenic osteomalacia that improved with chemotherapy, discuss this paraneoplastic syndrome, and review the medical literature regarding its etiology.
Introduction
W ith fewer than 100 cases reported in the m edical literature, oncogenic osteomalacia is a rare endocrinological paran eoplastic syndrom e characterized by defective bone m ineralization from renal phosphate loss. Tum or elaboration of a phosphaturic factor is th e pu tative m echa n ism . A lth ou gh occasio n ally reported in other tum or types, oncogenic osteom alacia is alm ost exclusively described in patients w ith benign tum ors of m esenchym al origin. Characteristically, patients present with signs and sym ptom s of osteom alacia, i.e., waddling gait, joint deform ities, bone pain, m uscle weakness, anorexia, fatigue and occasionally long bone fractures. Laboratory examination is notable for hypo phosphatem ia in the setting of inapp ropriate phosphaturia, but usually norm al PT H levels. 1,25-Vitam in D is inappropriately normal relative to the coexisting hypophosphatemia and is frankly depressed in m any cases. Evaluation with plain ® lm s usually reveals osteopenia, and occasionally the pseudofractures (Looser zones) and subperiosteal erosions seen in osteom alacia. Bon e scans also show the charac teristic ® nd in gs o f osteom alac ia, w hich is uptake that is diffu se and/or focal. Because the tum ors associated w ith this syndrom e are typically quite small (£ 1 cm), the clinical sym ptom s often precede the identi® cation of the tum or. In an otherwise healthy patient who presents with osteom alacia due to hyperphosphaturia, evaluation for an occult tum or should be con sid ered. For patien ts w ith kn ow n tum ors, surgical resection usually cures them of the syndrom e.
Case presentation
CB is a 68-year-old Caucasian wom an diagnosed in September 1993 with stage II B osteosarcom a of the left fem ur. She was treated with neoadjuvant cisplatin, ad riam ycin an d ifo sf am id e, follow ed by a lim bsp ar in g re sectio n reve alin g n early 100 % tu m o r n ecro sis. Po st-o p erative ly, sh e be gan a d ju van t chem otherapy, but this treatment was term inated in August 1994 after on ly one cycle of carboplatin because of persistent difficulties with wound healing and declining perform ance status. She resum ed a vigorous lifestyle including a 60-h work week and daily exercise. She was well until M ay 1996 w hen she developed a single pulm onar y m etastasis w hich was then su rgically resected. After a n orm al rou tine tum or sur veillance C T scan of the chest and upper a b d o m e n i n Ja n u a r y 1 9 9 7 , s h e p r e se n te d i n Febr uary 1997 to her o ncolog ist com plainin g of painful low er extrem ity ed em a an d bilateral an kle pain. H er exam ination was n otable fo r 2+ bilateral tender pitting edem a, tender an kles, but no stigm ata of heart failu re, hepatic failu re, nephrotic synd rom e, or d eep ven ous throm boses. A dd ition ally, she had painless proxim al in terphalangeal joint swellin g an d signi® cant ulnar deform ity of her m etacarpal phalangeal joints. Laboratory studies revealed signi® cant hyp o p h o s p ha tem ia ( 1.5 m g/ d l; n o r m al ra n g e, 2.6± 4.4), borderline hypocalcemia (8.3 m g/dl; normal range, 8.1± 10.2), and a m ildly elevated alkaline phosphatase (200 U /l; norm al range, 51± 153). O f note, her ser u m so d iu m (1 36 m eq /l; n o r m al r an g e, 134± 149), bicarbo nate (25 m eq/l; n or m al range, 23± 30), potassium (4.1 m g/dl; normal range, 3.5± 5.2), magnesium (2.2 m eq/l; norm al range, 1.6± 2.5), and creatinine (0.5 m g/dl; norm al range, 0.5± 1.4) were norm al. Additionally, both her parathyroid horm one (PT H) and 1,25(O H) 2 -vitam in D levels were normal (57 pg/m l; norm al range, <60; and 27 pg/m l; normal range, 15± 60, respectively). Plain ® lm s of the ankles revealed osteopenia, and a bone scan (see Fig. 1 ) revealed sym m etrical uptake in the joints of the hands, feet and spine. Her clinical sym ptoms and hypo phosphatem ia were relatively refractory to high doses of oral phosphate (500 mg elem ental phosph orus daily) but her edema im proved with lasix (20 m g daily).
In M arch, the patien t w as se en at the E nd ocrinology C linic where a 24-h urine revealed both inappropriate phosph aturia (777 m g; norm al range, 500± 1500) and calciuria (262 m g; n or m al range, 100± 200) given her serum values. Additionally, there was m ild glycosuria (1.05 g; norm al range, 0.0± 0.5), m ild proteinuria (0.15 g; norm al range, 0.05± 0.1), and trace elevation of urinary glycine. N o other am ino acids were detected. N otably, a review of the patient's extensive laboratory evaluation prior to and after surger y, and chemotherapy at her initial diagnosis of osteosarcom a in 1993, revealed no sim ilar abnorm alities. Bone densitom etry of her lum bar spine (L 2± L4) and her fem oral neck revealed severe osteoporosis. The diagnosis of osteomalacia was assum ed and, given her sarcom a histor y, the etiologies considered were oncogenic osteom alacia or, less likely, a renal tubular defect (e.g., Fanconi syndrom e or chronic toxicity) from prior chem otherapy (ifosfam ide). T he patient's course was not consistent with the Fanconi syndrome, p r im a r ily b eca u se h er hy p o p h o sp h ate m ia w as temporally distant from ifosfam ide treatment. Further, her am inoaciduria was negligible, and she had no evidence of potassium , m agnesium or bicarbonate wasting that would accom pany a m ore generalized proximal tubular defect.T he patient's course was also not consistent with a chronic tubulopathy from ifosfam ide, since her severe phosphate wasting was out of proportion to other evidence of proxim al tubulopathy and was unresponsive to phosphate repletio n , u n ch a ra cter istic o f p rev io u s ly d escr ib ed ifosfam ide-induced renal toxicity. 1 W hile som e degree of chronic tubular dam age from prior ifosfam ide and cisplatin was alm ost certain, ifosfam ide toxicity alone was felt unlikely to explain the acute onset and refractor y hyp ophosph atemia. G iven the working diagnosis of oncogenic osteom alacia, the endocrinology consultants recom m ended evaluation for possib le recurrent tumor, increased her dose of phosphate supplem ent to 1500 m g of elemental phospho rous daily and added vitamin D (800 U daily) and calcium carbonate (1500 m g daily).
Her hypo phosphatem ia did not im prove and a chest CT obtained in M ay revealed a left hilar m ass and a single large liver lesion, both suspicious for recurrent or a second m alignancy. In June m ultiple liver lesions and an obstructing pancreatic head lesion were noted, and biopsies of both locations were consistent w ith m etastatic osteosarcom a. W ithin 2 weeks of a single dose of adriamycin* (30 m g/m 2 ) given in July 1997, th e p atien t' s ser u m p h o sp h ate in crea sed in to the norm al range for the ® rst time since diagnosis of the syndrom e 6 m onths previously. H owever, the norm alization was¯eeting as it declined w ithin the subsequent 2 weeks. Later that m onth the patient developed thoracic spin al cord com pre ssion an d expired in August 1997 while enrolled in a hom e hospice. Table 1 contains a timeline of her disease, electrolyte values and m edical interventions. W hile the patient's m ean phosphate level during her period of osteom alacia (preceding the dose of adriam ycin) was 1.76 m g/dl, the m ean phosphate level after the single dose of adriamycin until death was 3.82 m g/dl. A post-adriam ycin 24-h urine for phosph ate was not collected.
Discussion
O steom alacia is a disorder of defective m ineralization of osteoid, organic bone m atrix. Since osteoid is m ineralized to bone through deposition of crystals com pose d of calcium an d phosphate, pro longed de® ciency of phosphate, calcium , or both, can beget osteomalacia. Chronic hypophosphatem ia results from inadequate intake or excessive loss and presents in inherited or acquired form s. Inadequate phosphate intake can be the result of extensive intestinal disease, the presence of phosphate binders in the diet, or secondar y to vitam in D de® ciency (due to low dietary intake, lack of sun exposure, renal or hepatic disease, and inherited disorders of vitam in D m etabolism ). Excessive urinary loss due to renal tubular dysfu nction can be inherited (e.g., autosom al recessive and X -lin k ed hy p o p h o sp h atem ic r ick ets, F a n co n i syndrom e) or acquired (e.g., renal tubular acidosis, toxic dam age by heavy m etals or certain chem otherape utic agen ts, an d tum or-in duced osteom alacia). Chronic hyp ocalcemia as a result of intestinal disease, abnormalities of vitamin D and parathyroid horm one, or system ic acidosis is an unusual cause of osteom alacia since symptoms of hyp ocalcem ia often result in earlier m edical attention and are only rarely seen in hypo parathyroidism and pseudohyp oparathyroidism .
T here are several hyp otheses for the m echanism of urinary phosph ate loss in oncogenic osteom alacia, with a hum oral m echanism by far the m ost com pelling based on clinical observations and experim ental data.T he clinical observations that support a humoral mechanism are that the culprit tum ors are often sm all and rem ote from the kidney, that tum or rem oval results in both rapid resolution of phosph aturia and in rapid skeletal rem in eralization, and that som e culprit tum ors appear to have neurosecretory granules on EM suggesting peptide horm one production.
2,3
In vivo and in vitro experim ents suggest the presence of a transm ittable phosphaturic factor. Investigators report phosphaturia in dogs and rats injected with tum or extracts 4± 6 and in athym ic m ice transplanted with tumor. 7 In single cell assays, investigators have described inhibition of both renal tubular sodiumdependent phosph ate transport 8, 9 and renal tubular 25(OH )D-1a -hyd roxylase when m edia from tum or cell cultures were added to cultures of anim al renal tubule cells. 7 These experim ents resonate w ith the clin ical ® n din gs o f p ho sph atu r ia an d decre ase d 1,25 (O H ) 2 -vita m in D in p atie n ts w ith th ese neoplasm s. However, whether the circulating factor has PT H-like activity is still unclear: tum or extracts have stim ulated cAM P in som e cases 8, 10 but not in others. 4, 9 T he m ainstay of m anagem ent of oncogenic osteom alacia has been rem oval of tum or through com plete surgical resection. Since the condition is usually associated with localized benign tum ors and n ot m etastatic m alignant disease, this app roach is usually successful. U nfortunately, our patient had m etastatic m alignant disease that was not resectable. However, the fact that tum or-spe ci® c chemotherapy was effective in at least transiently im proving her hypo phosphatem ia m ay support the theor y that oncogenic osteom alacia is paran eoplastic in origin. However, w hy th e p atien t' s tu m o r p ro g ressed w h ile h er phosphate was still in the norm al range is not clear. It Table 1 m ay be that the kinetics of the putative paraneoplastic phosphaturic factor and the kinetics of the tum or are not equal.
Conclusion
We report an atypical case of the rare entity oncogenic osteom alacia. The case was atypical because it was asso ciated w ith a m alignant tum or, because the syndrom e presented only w ith a second recurrence of the tum or, not with its initial presentation or ® rst relapse, and because it transiently im proved w ith chemotherapy. Like others with this paraneoplastic syndrom e, our patient had characteristic clinical, laborator y and radiograph ic ® ndings of hyperphosphaturic osteom alacia. W hile the pathophysiology of oncogenic osteom alacia is still not entirely clear, a paraneoplastic etiology has been proposed. T hrough our report of a patient's transient resolution of hypophosphatem ia coin cid ent w ith chem otherapy, we provide further evidence to suggest that this syndrom e m ay be paran eoplastic in origin.
